BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9951492)

  • 1. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
    Larkin G; Lightman S
    Ophthalmology; 1999 Feb; 106(2):370-4. PubMed ID: 9951492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the treatment of scleritis.
    Sen HN; Suhler EB; Al-Khatib SQ; Djalilian AR; Nussenblatt RB; Buggage RR
    Ophthalmology; 2003 Sep; 110(9):1750-5. PubMed ID: 13129873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil therapy for inflammatory eye disease.
    Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
    Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.
    Siepmann K; Huber M; Stübiger N; Deuter C; Zierhut M
    Graefes Arch Clin Exp Ophthalmol; 2006 Jul; 244(7):788-94. PubMed ID: 16163494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis].
    Greiner K; Varikkara M; Santiago C; Forrester JV
    Ophthalmologe; 2002 Sep; 99(9):691-4. PubMed ID: 12219257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil: a dermatologic perspective.
    Mydlarski PR
    Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate Mofetil Therapy in Refractory Inflammatory Eye Disease.
    Cuchacovich M; Solanes F; Perez C; Verdaguer JI; Verdaguer J; Castiglione E; Carpentier C; Traipe L; Villarroel F
    J Ocul Pharmacol Ther; 2016; 32(1):55-61. PubMed ID: 26562247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
    Sobrin L; Christen W; Foster CS
    Ophthalmology; 2008 Aug; 115(8):1416-21, 1421.e1. PubMed ID: 18221998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation.
    Lau CH; Comer M; Lightman S
    Clin Exp Ophthalmol; 2003 Dec; 31(6):487-91. PubMed ID: 14641155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for ocular inflammation.
    Daniel E; Thorne JE; Newcomb CW; Pujari SS; Kaçmaz RO; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Foster CS; Jabs DA; Kempen JH
    Am J Ophthalmol; 2010 Mar; 149(3):423-32.e1-2. PubMed ID: 20042178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.
    Baltatzis S; Tufail F; Yu EN; Vredeveld CM; Foster CS
    Ophthalmology; 2003 May; 110(5):1061-5. PubMed ID: 12750115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
    Galor A; Jabs DA; Leder HA; Kedhar SR; Dunn JP; Peters GB; Thorne JE
    Ophthalmology; 2008 Oct; 115(10):1826-32. PubMed ID: 18579209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
    Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G
    Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in liver transplantation.
    McDiarmid SV
    Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease.
    Choudhary A; Harding SP; Bucknall RC; Pearce IA
    J Ocul Pharmacol Ther; 2006 Jun; 22(3):168-75. PubMed ID: 16808677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil in the treatment of chronic non-infectious, non-necrotizing scleritis.
    Kolomeyer AM; Ragam A; Shah K; Jachens AW; Tu Y; Chu DS
    Ocul Immunol Inflamm; 2012 Apr; 20(2):113-8. PubMed ID: 22409564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
    Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
    Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent].
    Yashima Y; Ohgane T
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):131-7. PubMed ID: 11233304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.